CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
The FDA granted regular approval to venetoclax (Venclexta, AbbVie and Genentech) for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, with or without 17p deletion, who have received at least one prior therapy.
Pages: 1 2
The FDA granted regular approval to venetoclax (Venclexta, AbbVie and Genentech) for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, with or without 17p deletion, who have received at least one prior therapy.